DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Prognostic Biomarkers in Active Surveillance: Parsing Risk in Early Stage Prostate Cancer
[Technical Report, Final Report]
BETH ISRAEL DEACONESS HOSPITAL INC BOSTON MA
Pagination or Media Count:
While a majority of prostate cancers PCa remain clinically insignificant, some have the potential to metastasize and become lethal and therefore merit intervention. Thus, identification of men most at risk and most likely to benefit from therapy is a major clinical and public health challenge. Furthermore, identification of phenotypic subtypes amenable to strategies such as immunotherapy could enhance personalized treatment. During this period, we continued to expand our cohort of non-indolent active surveillance AS patients in order to provide a comparitor for the relatively quiet copy-number landscape we previously identified in indolent AS patients. We also investigated a novel phenotype of immunogenic localized PCa characterized by an apparent anti-tumor immune response. Finally, we investigated driver mutations in localized PCa and examined how these were affected by metastatic spread and treatment resistance.
[A, Approved For Public Release]